Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Google Cloud's commitment to AI-powered cancer research and Sun Pharma's partnership with a music icon.

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with German laboratory Labor Dr.